Interleukin 6 News and Research

RSS

Interleukin-6 (IL-6) is a protein that in humans is encoded by the "IL6" gene. IL-6 is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation.

New injectable 'biogel' may become new weapon against cancer

A new injectable "biogel" is effective in delivering anti-cancer agents directly into cancerous tumours and killing them. This technology, developed by researchers at the University of Montreal Hospital Research Centre, has already been successfully tested in the laboratory. If it works in patients, the therapy could one day revolutionize treatment for many forms of cancer.

20 Nov 2015

Pathophysiological biomarkers predict PAH prognosis

Researchers have identified three biomarkers that signify an increased risk of death or requirement for lung transplantation in patients with pulmonary arterial hypertension.

13 Nov 2015

Tocilizumab drug offers potential treatment for patients with polymyalgia rheumatics

A drug approved to treat rheumatoid arthritis, tocilizumab (Actemra, Genentech), is a potential new therapy for patients with polymyalgia rheumatica, according to an open-label, phase II study presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on November 10.

11 Nov 2015

No progression in joint damage in 84% of psoriatic arthritis patients

Novartis announced today new results for Cosentyx® (secukinumab) showing no further progression in joint damage in 84% of patients with psoriatic arthritis (PsA). In addition, Cosentyx maintained a treatment response in joint and skin disease, physical function and quality of life in patients over two years of treatment. These results from the extension phase of the FUTURE 1 study were presented at the 2015 Annual Meeting of the American College of Rheumatology (ACR) in San Francisco, United States.

9 Nov 2015

Novartis’ Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients

Novartis announced today late-breaking two year results for Cosentyx® (secukinumab) showing up to 80% of patients with ankylosing spondylitis (AS) had no radiographic progression in the spine on x-ray assessment. This is the first time that data on structural spinal progression in AS have been presented for an interleukin-17A (IL-17A) inhibitor.

9 Nov 2015

Combatting viral and bacterial lung infections with volatile anesthetics: an interview with Dr Chakravarthy

Inhaled anesthetics are fairly common all over the world for minor and extensive surgical procedures in patients of all age groups. In the olden days when anesthesia was first developed, ether was the first inhaled anesthetic. That has been replaced, with the more recent discoveries of sevoflurane, isoflurane, and desflurane.

9 Nov 2015

Nucala (mepolizumab) approved for treatment of asthma patients

The U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older. Nucala is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines.

5 Nov 2015

Scientists one step closer to developing new treatment for inflammatory bowel disease

For patients with inflammatory bowel disease, the possibility of taking a single pill to bring long-lasting relief might seem too good to be true. Scientists at the Lewis Katz School of Medicine at Temple University are on the brink of making that happen, thanks to a recent proof-of-concept study, in which the severity of a form of inflammatory bowel disease in mice was dramatically reduced with one oral dose of a protein isolated from a bacterial biofilm.

30 Oct 2015

Virginia Tech researchers study how specific cytokine influences gene expression patterns in T helper cells

Environment can make all the difference in behavior - even at the cellular level. Scientists at the Virginia Tech Carilion Research Institute have discovered even a small shift in environmental factors can change how a cell in the immune system matures.

28 Oct 2015

Magnesium sulfate has protective effect on maternal fever during labor

Women who received magnesium sulfate during labor were less likely to develop maternal fever, a condition that can lead to a variety of complications in newborns including difficulty breathing, seizures, cerebral palsy and a condition known as "floppy baby syndrome," characterized by inadequate muscle tone, according to a retrospective study presented at the ANESTHESIOLOGY 2015 annual meeting in San Diego.

26 Oct 2015

CHMP recommends approval of Cosentyx in Europe to treat patients with AS and PsA, says Novartis

Novartis announced today that the Committee for Medicinal Products for Human Use has recommended the approval of Cosentyx (secukinumab) in Europe to treat ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients.

26 Oct 2015

Biological sensor protein could help combat diabetes, obesity

In the study, researchers showed a protein called NLRP1 is switched on when increased dietary energy (food) intake triggers the cell to become 'unstable'.

23 Oct 2015

Culprit B cells identified for MS

Researchers have identified a subset of B cells that contribute to multiple sclerosis pathology independently of antibody production.

22 Oct 2015

Breakthrough research suggests that female sex hormone may save lives on the battlefield

Breakthrough research suggests a female sex hormone may be the key to saving lives on the battlefield, where between 2001 and 2011 more than 80 percent of potentially preventable U.S. war injury deaths resulted from blood loss.

22 Oct 2015

Bacterium that causes Q fever associated with increased risk of lymphoma

The bacterium that causes Q fever, an infectious disease that humans contract from animals, is associated with an increased risk of lymphoma, according to a study published online today in Blood, the Journal of the American Society of Hematology.

13 Oct 2015

Phase III trial data shows Novartis’ Cosentyx maintains clear skin, sustained efficacy in psoriasis patients

Novartis announced today new late-breaking data demonstrating that CosentyxTM provides high levels of skin clearance and sustained efficacy in patients with moderate-to-severe plaque psoriasis while maintaining a favorable safety profile across three years.

13 Oct 2015

Provepep synthesizes bioactive homodimer form of IL-10 using SEA peptide ligation technology

Provepep, the peptide business unit of Provence Technologies Group, a specialist fine chemistry research group, today announces that it has successfully synthesized tens of mg of bioactive homodimer form of IL-10.

7 Oct 2015

Immune system protein has potential to prevent onset of aggressive form of rheumatoid arthritis

Scientists have discovered what they believe has the potential to prevent the onset of an aggressive and hard-to-treat form of rheumatoid arthritis - a condition that affects 700,000 adults in the UK.

7 Oct 2015

IU-led scientists discover new gene that increases Alzheimer's disease risk

In a newly published study, a multi-institutional team led by scientists at the Indiana University School of Medicine have discovered an immune system gene associated with higher rates of amyloid plaque buildup in the brains of Alzheimer's patients and older adults at risk for the disease.

6 Oct 2015

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers and published online today in the New England Journal of Medicine.

1 Oct 2015

Interleukin 6 News and Research

Further Reading

New injectable 'biogel' may become new weapon against cancer

Pathophysiological biomarkers predict PAH prognosis

Tocilizumab drug offers potential treatment for patients with polymyalgia rheumatics

No progression in joint damage in 84% of psoriatic arthritis patients

Novartis’ Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients

Combatting viral and bacterial lung infections with volatile anesthetics: an interview with Dr Chakravarthy

Nucala (mepolizumab) approved for treatment of asthma patients

Scientists one step closer to developing new treatment for inflammatory bowel disease

Virginia Tech researchers study how specific cytokine influences gene expression patterns in T helper cells

Magnesium sulfate has protective effect on maternal fever during labor

CHMP recommends approval of Cosentyx in Europe to treat patients with AS and PsA, says Novartis

Biological sensor protein could help combat diabetes, obesity

Culprit B cells identified for MS

Breakthrough research suggests that female sex hormone may save lives on the battlefield

Bacterium that causes Q fever associated with increased risk of lymphoma

Phase III trial data shows Novartis’ Cosentyx maintains clear skin, sustained efficacy in psoriasis patients

Provepep synthesizes bioactive homodimer form of IL-10 using SEA peptide ligation technology

Immune system protein has potential to prevent onset of aggressive form of rheumatoid arthritis

IU-led scientists discover new gene that increases Alzheimer's disease risk

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News